RxDoctor Payments Data

Luis Antillon

Optometrist · Tucson, AZNPI 1285300970

Payments from drug & device makers

$3,659in general payments, 2019–2025

Across 134 payments — averaging $27.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$761
  • Alcon$473
  • Oyster Point Pharma, Inc.$410
  • Amgen$361
  • Bausch & Lomb Americas Inc.$316
  • Glaukos Corporation$271
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,659100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,659 in reported general payments places this provider in the 85th percentile of 1,134 optometrist providers in Arizona.

See all optometrist providers in Arizona

Medicare billing

Part B allowed, 2024
$90,507
Medicare patients
419
Services billed
968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast78$58,659
RestasisCyclosporine64$49,152
MieboPerfluorohexyloctane/Pf21$22,877
XdemvyLotilaner11$22,249
CequaCyclosporine11$14,767
Cyclosporine24$8,119
Tobramycin-DexamethasoneTobramycin/Dexamethasone97$4,371
Prednisolone Acetate120$3,908
Loteprednol Etabonate19$2,451
MoxifloxacinMoxifloxacin Hcl51$1,990
Latanoprost206$1,830
Brimonidine Tartrate81$1,020
ValacyclovirValacyclovir Hcl21$963
ErythromycinErythromycin Base79$957
Timolol Maleate46$329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$316$81,53699 claims
AbbVieRestasis$78$49,15264 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$105$22,24911 claims
Sun Pharmaceutical Industries Inc.Cequa$761$14,76711 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$29$2,45119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,134 optometrist providers in Arizona.

Other optometrist in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →